Suche
Mein Konto
Enterin and Parkinson's Virtual Biotech are collaborating to study the effects of ENT-01 on PD-associated dementia
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases, announces a collaboration with Parkinson’s Virtual Biotech, the drug development and research arm of Parkinson’s UK. A new phase 2 study is studying the effects of ENT-01 on Parkinson's-related dementia. In January 2022, Enterin announced statistically significant results from a randomized, placebo-controlled Phase 2b trial [KARMET] in 150 subjects with PD. In this study, a subset of participants suffered from PD-associated dementia. Patients treated with ENT-01 showed improvement in cognitive...
![Enterin Inc., ein in Privatbesitz befindliches biopharmazeutisches Unternehmen mit Sitz in Philadelphia und klinischer Phase, das neuartige Behandlungen für neurodegenerative und metabolische Erkrankungen entwickelt, gibt eine Zusammenarbeit mit Parkinson’s Virtual Biotech bekannt, der Arzneimittelentwicklungs- und -forschungsabteilung von Parkinson’s UK. In einer neuen Phase-2-Studie werden die Auswirkungen von ENT-01 auf Parkinson-bedingte Demenz untersucht. Im Januar 2022 gab Enterin statistisch signifikante Ergebnisse einer randomisierten, placebokontrollierten Phase-2b-Studie bekannt [KARMET] bei 150 Probanden mit PD. In dieser Studie litt eine Untergruppe der Teilnehmer an PD-assoziierter Demenz. Patienten, die mit ENT-01 behandelt wurden, zeigten im Vergleich zu denen, die Placebo erhielten, eine Verbesserung der kognitiven …](https://institut-der-gesundheit.com/cache/images/Das-Mortalitaetsvorhersagemodell-fuer-Demenzpatienten-kann-bei-Entscheidungen-zur-Versorgung-am-1100.webp)
Enterin and Parkinson's Virtual Biotech are collaborating to study the effects of ENT-01 on PD-associated dementia
Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases, announces a collaboration with Parkinson’s Virtual Biotech, the drug development and research arm of Parkinson’s UK. A new phase 2 study is studying the effects of ENT-01 on Parkinson's-related dementia.
In January 2022, Enterin announced statistically significant results from a randomized, placebo-controlled Phase 2b trial [KARMET] in 150 subjects with PD. In this study, a subset of participants suffered from PD-associated dementia. Patients treated with ENT-01 showed an improvement in cognitive function compared to those who received placebo. A statistically significant benefit was observed six weeks after treatment, suggesting that ENT-01 has the potential to influence disease progression.
Our studies have demonstrated the clinical benefit of ENT-01 in a range of Parkinson's-related non-motor symptoms such as gastrointestinal dysfunction, dementia, psychosis, sleep architecture and circadian rhythm, all of which are commonly associated with Parkinson's."
Denise Barbut, co-founder, president and CMO of Enterin
The pathological process in PD dementia (PDD) involves the presence of alpha-synuclein (αS) aggregates in the enteric nervous system (ENS) and central nervous system (CNS). Inhibition of αS aggregation in the ENS may reduce the progressive disease process in both the ENS and CNS and slow the progression of Parkinson's disease. ENT-01 is administered orally and acts locally on the ENS. It dissolves αS aggregates and inhibits their formation, restoring the firing potential of enteric neurons. This effectively improves the neuronal signal transmission between the intestine and the brain via the vagus nerve.
“We are delighted to be working with Enterin as part of Parkinson’s Virtual Biotech to develop a potential new treatment for Parkinson’s-related dementia,” said Arthur Roach, Research Director at Parkinson’s UK. "Parkinson's is the fastest growing neurological disease in the world and there is currently no cure. The medications we have today can only treat and relieve some of the more than 40 symptoms."
"Although Parkinson's disease is more commonly associated with motor symptoms such as tremor, our community has asked us to make new and better treatments for Parkinson's dementia a priority. We are encouraged by the clinical results that Enterin's work has produced to date and look forward to what lies ahead." clinical trial which will have sites in both the UK and America.”
“Enterin is very grateful to partner with such a prestigious and respected organization,” said David McCullough, CEO of Enterin. "We have worked closely with Parkinson's UK and their clinical advisors to design a clinical trial to evaluate ENT-01 in PD dementia. We hope to offer these patients a new therapeutic option."
Source:
.